Oncology Institute, Inc. (The) (TOI)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$5.91-4.21%
Close 2026-08-31 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · TOI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks TOI against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on increasing revenue through capitated contracts and specialty pharmacy growth while moving towards sustained positive Adjusted EBITDA.
Stated as a priority in 3 of last 3 quarters. Revenue increased from $104.4 million in 2025-Q1 to $161.3 million in 2026-Q2 (+35%), with Adjusted EBITDA improving from a loss of $4.1 million in 2025-Q2 to positive $229 thousand in 2026-Q2. Management has consistently emphasized revenue growth and sustainable profitability, and the financials show delivering progress on this trajectory.
“CEO: 'Revenue up 35% year over year and Adjusted EBITDA turning positive in Q2... raising full-year outlook.'”
“CEO: 'Delivering 41% year over year revenue growth... reaffirming guidance and confident in sustainable profitability.'”
“CEO: 'Strong revenue growth and progress towards profitability.'”
Grow the number of capitated lives under value-based contracts, including new delegated contracts outside Florida and exclusivity agreements.
Stated as a priority in 3 of last 3 quarters. Lives under value-based contracts grew from 1.9 million in 2025-Q2 to 2.1 million in 2026-Q2. Management highlighted new delegated contracts outside Florida and exclusivity adding ~230,000 lives in California, indicating delivering progress on expanding capitated contracts.
“CEO: 'Signed first delegated contracts outside Florida, exclusivity agreement adding ~230,000 capitated lives.'”
Complete refinancing transactions to repay convertible notes, improve liquidity, extend debt maturities, and avoid shareholder dilution.
Newly stated in 2026-Q3 (July 2026). Management completed refinancing repaying an $86 million convertible note with a $75 million term loan, improving liquidity and extending debt maturities without diluting shareholders. This transaction strengthens the financial position as intended.
Deploy Starling Nexus provider portal to strengthen provider engagement and support adherence to clinical pathways.
Stated as a priority in 2 of last 3 quarters. Management announced preparing to launch the Starling Nexus provider portal in mid-August 2026 to enhance provider engagement and clinical pathway adherence. No financial metrics yet available to measure delivery, indicating early stage progress.
“Preparing to launch proprietary provider portal Starling Nexus in mid-August to strengthen provider engagement.”
Oversee capital structure actively, including issuing warrants and managing equity to support financial strategy and shareholder interests.
Over the trailing year it converted -0.00x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.
“Contract expansion bringing total Medicare Advantage lives to 200,000 across 25 Florida counties effective July 1, 2026.”
“Management discussed growth in capitated contracts and lives under value-based care.”
“Preparing to launch proprietary provider portal designed to strengthen provider engagement and drive adherence.”